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preservation, airway healing, acute bacterial and viral
infections, and immunosuppression have been resolved
to the extent that early and 1-year mortality rates are
quite reasonable (95% and 76%, respectively).2
However, long-term survival after lung transplantation
L ung transplantation has evolved over the past 15years to become recognized treatment for various
end-stage respiratory conditions including cystic fibro-
sis, pulmonary hypertension, pulmonary fibrosis, and
emphysema.1 The perioperative issues including lung
Objectives: We wished to determine whether early rejection after lung
transplantation as assessed by surveillance transbronchial biopsy pre-
dicts for survival. Methods: Between 1990 and 1997, 96 consecutive
patients had lung transplantation: 89 had a minimum 1-month follow-
up. For 71 consecutive patients we have 1-year follow-up and for 69
patients we have the results of the first 3 biopsies. Cytomegalovirus sta-
tus, bronchiolitis obliterans prevalence, and use of total lymphoid irra-
diation are noted. Biopsies were done at 1 week and 1, 3, and 6 months.
Standard immunosuppression consisted of induction antilymphocyte
globulin and high-dose methylprednisolone induction for 1 week and
standard maintenance triple therapy. Acute rejection treatment was
with pulse methylprednisolone. Bronchiolitis obliterans syndrome was
treated with total lymphoid irradiation and a change to tacrolimus and
mycophenolate. Blinded grading using International Society for Heart
and Lung Transplantation classification was done retrospectively.
Results: Survival at 1 month and 1, 2, and 3 years for the 96-patient
cohort with 1-year follow-up was 93%, 74%, 62%, and 56%. Survival
was not significantly different for subsets with rejection on any combi-
nation of the first 3 biopsies (1/3, 2/3, 3/3) or absence of rejection on the
first 3 biopsies. Ninety-one positive biopsy results were graded. Eighteen
of 71 patients had one or more moderate or severe rejection episodes
without survival difference relative to the others. There was no statisti-
cally significant association between acute rejection on the first 3 sur-
veillance biopsy results and bronchiolitis obliterans. Conclusions:
Intensive induction and maintenance immunotherapy with surveillance
transbronchial biopsies and aggressive treatment of acute rejection is
associated with a survival similar to that of patients without early acute
rejection. This regimen appears to uncouple the association between
early acute rejection and bronchiolitis obliterans. Further study may
elucidate this mechanism. (J Thorac Cardiovasc Surg 2000;119:27-38)
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remains unsatisfactory with a 5-year survival of 40%
reported in the most recent United Network for Organ
Sharing annual report.2 The primary reason for attrition
is bronchiolitis obliterans, the pathologic hallmark of
chronic lung rejection. Once this diffuse fibrotic
process has developed, patients become quite dyspneic,
and no therapy to date has succeeded in reversing the
clinicopathologic condition. Most patients will die of
either respiratory insufficiency or superimposed infec-
tion. Predictors of bronchiolitis obliterans, and there-
fore ultimately of patient death, have been identified by
several investigators. Bando and colleagues3 in
Pittsburgh noted that airway ischemia, cytomegalovirus
disease, and either 1 or more episodes of moderate to
severe acute rejection (grade 3/4) or 3 or more episodes
of grade 2 (or greater) acute rejection were significant
risk factors for the development of bronchiolitis oblit-
erans by univariate analysis. In their multivariate analy-
sis, only the finding of 3 or more episodes of grade 2
(or greater) acute rejection was associated with the
development of bronchiolitis obliterans.
The role of transbronchial biopsies in providing
histologic confirmation of acute lung rejection is well
established.4-6 The utility of routine surveillance trans-
bronchial biopsies particularly in the late postoperative
period has been debated.6-9 The morbidity of the proce-
dure is relatively low, but whether it provides clinically
relevant information is unclear. Certainly the informa-
tion obtained must be interpreted carefully. Immediately
after the transplant, pathologic changes related to
the implantation, including the ischemia-reperfusion
process, are typically seen. If there are signs of infec-
tion, it may be difficult to diagnose rejection. Further-
more, in this era of cost awareness, the expense of the
biopsies must be considered.
Our study was designed to look at the potential pre-
dictive value for survival of the first 3 surveillance
transbronchial biopsies after lung transplantation. This
was a retrospective analysis of data collected in our
thoracic surgery database.
Methods
We performed 96 consecutive single or double (sequential
bilateral) lung transplants between 1990 and 1997. The trans-
plants were done by standard techniques including telescop-
ing and wrapping of the airway anastomosis.1 Cardio-
pulmonary bypass was used when necessary to support the
patient during implantation.
The routine immunosuppressive regimen at our institution
includes induction with either Minnesota antilymphocyte
globulin or antithymocyte gamma globulin (ATGAM,
Pharmacia Upjohn, Kalamazoo, Mich) for 1 week and high-
dose methylprednisolone (1 gm intravenously intraoperative-
ly before opening the circulation to the transplanted lung,
then 125 mg intravenously 3 times a day for 1 week). The
antithymocyte gamma globulin is administered at a dosage of
15 mg/kg and decreased to 10 mg/kg if the total lymphocyte
count falls below 100/mm3 or the platelet count falls below
50,000/mm3. Triple-drug maintenance therapy consists of
prednisone 60 mg/day beginning at 1 week and tapering to 20
mg/day over 12 weeks, azathioprine 50 mg twice a day
adjusted for leukopenia (white blood cell count <4000/mm3)
beginning on postoperative day 7, and cyclosporine A (INN:
ciclosporin) begun the night of the operation by intravenous
infusion and converted to the oral route with target levels of
300 to 350 ng/mL. Rejection episodes at our institution are
treated with pulse methylprednisolone (1 gm intravenously
daily for 3 days). Over the past 2 years, maintenance therapy
has been changed to mycophenolic acid and tacrolimus after
2 moderately severe or severe episodes. In addition, those
patients in whom bronchiolitis obliterans syndrome or bron-
chiolitis obliterans developed, as noted in Tables I and II,
were treated with total lymphoid irradiation (0.4 Gy twice a
day 2 times per week for 5 weeks; total dose 8 Gy using
inverted Y and pelvic ports).
Transbronchial biopsies during the first year after the trans-
plant were done on a standard schedule as well as when there
was a decline in pulmonary function in the absence of diag-
nosed infection. We took 5 to 6 biopsy samples per procedure
(≥100 alveoli)10 and focused our attention on the lower and
middle lobes on the right and the lingula and lower lobe on
the left. For the first 24 patients, biopsies were done at 1
week, 1 month, 3 months, 6 months, and 12 months from the
time of transplantation. After these first patients, the surveil-
lance transbronchial biopsies were done at 1 month, 3
months, 6 months, and 12 months. The 1-week biopsy was
omitted because in most cases the changes observed were
related to the implantation.
Cytomegalovirus prophylaxis was used for any patient in
whom a donor-recipient mismatch existed or if both the
donor and recipient had positive cytomegalovirus status (n =
44, see Tables I and II). In those cases, ganciclovir was given
intravenously for 1 year: an induction dose (5 mg/kg twice a
day) for the first month followed by maintenance therapy (5
mg/kg daily) for the last 11 months.
Our prospective thoracic database was reviewed in addition
to patient charts and pathology and microbiology records to
capture morbidity and mortality data and important clinical
events such as infection, decline in pulmonary function, and
the results of transbronchial biopsies. In a blinded fashion,
one of us (L.K.) reviewed the transbronchial biopsy speci-
mens for verification: the data are reported according to the
International Society for Heart and Lung Transplantation
(ISHLT) revised grading schema.10
Bronchiolitis obliterans syndrome was defined according
to the ISHLT definition.11 The presence of bronchiolitis oblit-
erans was determined by transbronchial biopsy.
There were 96 consecutive patients who had lung trans-
plantation and had a potential minimum follow-up of 1 year.
This interval was chosen to focus on the association between
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early events and long-term outcome: bronchiolitis obliterans
and survival. These 96 patients make up the cohort for this
report. Seventy-one patients survived 1 year and make up the
subset for the bronchiolitis obliterans analysis.
Survival was tabulated by a Kaplan-Meier life table,12 and
statistical analysis was done by log-rank test. The JMP pro-
gram (SAS Institute, Inc, Cary, NC) was used for the compu-
tations and graphic display.
Results
The descriptive profiles, indications, and periopera-
tive results for the 96 consecutive patients who
received transplants during the study period, which
included an appropriate time interval to allow for at
least 1 year of follow-up, are displayed in Table III.
Seventy-one (74%) of the 96 patients survived 1 year
and therefore make up the subset for our analysis. The
minimum 1-year survival helps to focus the analysis on
those patients most likely to have the development of
chronic rejection. Analysis of results in the patients
who did not survive 1 year demonstrates there was no
difference in the incidence of acute rejection in this
group (n = 25) versus that in those 71 patients who sur-
vived 1 year (P = .40).
Median follow-up was 40 months (range 12-100
months). Sixty-nine patients had 3 early biopsies (≤6
months), and 2 patients only had 1. In 32 patients acute
rejection was demonstrated on the 1-month trans-
bronchial biopsy. The results of the first 3 trans-
bronchial biopsies in this group along with the survival
and absence or presence of bronchiolitis obliterans and
cytomegalovirus disease are shown in Table I. The
actuarial survival for those patients with rejection
demonstrated on the 1-month biopsy versus those with-
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Table I. Patients (n = 32) with evidence of rejection on 1-month biopsy
Survival CMV status, CMV 
days 1-Mo 3-Mo 6-Mo recipient/donor, disease 
Patient Status from TX biopsy biopsy biopsy OB TLI pre-TX post-TX
4 D 714 Pos Neg Pos Pos No Neg/Neg Neg
5 D 591 Pos Pos Pos Neg No Pos/Neg Neg
7 A 3088 Pos Neg Neg Pos No Neg/Neg Neg
8 D 806 Pos Neg Neg Neg Yes Neg/Neg Neg
14 D 1852 Pos Pos Neg Neg No Neg/Pos Pos
18 A 2351 Pos Pos Pos Neg Yes Neg/Pos Neg
21 D 513 Pos Neg Neg Neg No Neg/Pos Neg
24 A 2115 Pos Pos Neg Pos No Neg/Neg Neg
26 D 1056 Pos Pos Pos Neg Yes Neg/Pos Neg
28 A 1879 Pos Pos Pos Neg Yes Neg/Neg Neg
31 A 1641 Pos Neg Neg Pos No Neg/Neg Neg
33 A 1454 Pos Neg Neg Pos No Neg/Pos Neg
34 A 1604 Pos Pos Pos Neg Yes Neg/Neg Neg
37 A 1589 Pos Neg Pos Pos No Neg/Pos Neg
40 A 1548 Pos Neg Pos Pos Yes Neg/Pos Neg
41 D 536 Pos Pos Pos Neg No Pos/Pos Neg
42 A 1518 Pos Pos Pos Pos Yes Pos/Pos Neg
44 A 1473 Pos Neg Pos Pos No Neg/Pos Neg
46 A 1440 Pos Neg Neg Pos No Neg/Neg Neg
47 A 1405 Pos Pos Pos Pos No Neg/Pos Neg
48 A 1404 Pos Neg Pos Neg No Pos/Neg Neg
50 D 444 Pos Neg Neg Neg No Neg/Pos Neg
51 A 1308 Pos Pos NA Neg Yes Neg/Pos Neg
54 D 1249 Pos Neg Neg Neg No Neg/Neg Neg
55 A 1248 Pos Pos Pos Pos No Neg/Neg Neg
59 A 1150 Pos Neg Neg Pos No Neg/Neg Neg
61 A 1121 Pos Neg Neg Pos No Neg/Pos Neg
64 A 882 Pos Pos Pos Pos No Neg/Pos Neg
65 A 831 Pos Pos Pos Pos No Neg/Neg Neg
67 A 781 Pos Pos Neg Pos No Neg/Pos Pos
68 A 750 Pos Neg Pos Pos No NA/NA Neg
69 A 746 Pos Pos Neg Pos No NA/NA Neg
Data as of April 1999. TX, Transplantation; OB, bronchiolitis obliterans; TLI, total lymphoid irradiation; CMV, cytomegalovirus; D, dead; Pos, positive; Neg, nega-
tive; A, alive; NA, not available.
out (n = 39) is graphed in Fig 1. There was no statisti-
cal difference in survival by log-rank test (P = .15).
Table II displays the characteristics, including the
prevalence of bronchiolitis obliterans, cytomegalovirus
disease status, and patient survival, for the 39 patients
who did not show rejection on the 1-month biopsy and
includes the 17 patients who did not show any evidence
of rejection on the first 3 consecutive biopsies. Fig 2
displays a survival graph for those who had no rejection
on the 3-month biopsy (n = 35) versus those who did
have rejection on the 3-month biopsy (n = 34). Again,
there was no statistical difference in survival by log-
rank test (P = .74). Fig 3 shows the survival of those
patients who showed acute rejection on the 6-month
biopsy (n = 34) versus those who did not (n = 33).
Again, no statistically significant difference was mea-
sured by log-rank test (P = .10).
Two hundred nine transbronchial biopsy samples
were examined by our pathologists. More than 95% of
these early biopsies were done for surveillance or to
follow up pulse therapy. All biopsy samples were
included in the analysis. Of the 209, 91 were interpret-
ed as positive for acute rejection. This represented
acute rejection occurring in 52 (73%) of 71 patients
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Table II. Patients (n = 39) without evidence of rejection on 1-month biopsy including 17 with no evidence on first
3 biopsies
CMV status,
Survival days 1-Mo 3-Mo 6-Mo recipient/donor, CMV disease 
Patient Status from TX biopsy biopsy biopsy TLI pre-TX post-TX
1 D 1188 Neg Neg Neg No Neg/Neg Neg
2 D 2024 Neg Neg Neg No Neg/NA Neg
3 D 1070 Neg Neg Neg No Neg/Pos Neg
6 A 3197 Neg Neg Pos No Neg/Neg Neg
9 D 1524 Neg Pos Neg No Neg/Neg Neg
10 A 2820 Neg Neg Pos Yes Neg/Neg Neg
11 D 778 Neg Pos Pos No Neg/Neg Neg
12 D 1439 Neg Pos Pos No Neg/Neg Pos
13 D 2633 Neg Neg Neg Yes Neg/Neg Neg
15 D 1230 Neg Pos Neg Yes Neg/Pos Neg
16 D 906 Neg Neg Pos No Neg/Neg Neg
17 D 725 Neg Pos Pos No Neg/Neg Neg
19 D 339 Neg Neg Neg No Neg/Pos Neg
20 A 2327 Neg Pos NA No Neg/Neg Neg
22 A 2204 Neg Neg Pos No Neg/Pos Neg
23 D 2137 Neg Pos Neg Yes Neg/Neg Neg
25 D 1991 Neg Neg Pos Yes Neg/Neg Neg
27 D 810 Neg Neg Neg No Neg/Neg Neg
29 A 1699 Neg Neg Pos No Neg/Pos Neg
30 A 1684 Neg Neg Neg Yes Neg/NA Neg
32 D 380 Neg NA NA No Pos/Neg Neg
35 D 1006 Neg Pos Pos Yes Pos/NA Neg
36 A 1596 Neg Neg Neg No Neg/Pos Neg
38 D 445 Neg Pos Neg No Neg/Neg Neg
39 A 1576 Neg Pos Pos Yes Neg/Neg Neg
43 D 365 Neg Neg Neg No Neg/Pos Pos
45 A 1447 Neg NA NA No Neg/NA Neg
49 A 1402 Neg Pos Pos Yes Neg/Pos Neg
52 A 1280 Neg Neg Neg No Pos/Neg Neg
53 A 1252 Neg Pos Neg No Neg/Pos Neg
56 A 1220 Neg Pos Pos Yes Pos/Pos Neg
57 D 638 Neg Neg Neg No Neg/Pos Neg
58 A 1185 Neg Pos Pos No Neg/Pos Pos
60 A 1125 Neg Neg Pos No Neg/Pos Neg
62 D 943 Neg Pos Pos No Neg/Pos Neg
63 A 942 Neg Pos Pos No Neg/Pos Neg
66 A 806 Neg Pos Neg No Pos/Pos Neg
70 A 739 Neg Neg Neg No NA/NA Neg
71 D 416 Neg Pos Neg No NA/NA Neg
Data as of April 1999. TX, Transplantation; TLI, total lymphoid irradiation; CMV, cytomegalovirus; D, dead; Pos, positive; Neg, negative; A, alive; NA, not available.
during the first 6 months after lung transplantation.
Table IV displays the data on these patients with use of
the ISHLT revised grading system. Two of 71 patients
had 2 or more moderate (A3 or B3) or severe (A4 or
B4) episodes of acute rejection on the first 3 biopsies.
Two of 71 patients had severe acute (A4 or B4) rejec-
tion on at least 1 of the first 3 biopsies. Moreover, 5
(7%) of 71 patients had 2 or more episodes of mild
(A2) rejection.
Analysis looking at 1 or more episodes of A3 rejec-
tion or multiple A2 rejections demonstrated that they
did not predict the development of bronchiolitis oblit-
erans. The explanation for this other than a β statistical
error may be again that we saw a relatively low inci-
dence of A3 rejection events or of 2 or more A2 rejec-
tion events. We identified only 7% of our patients in
whom multiple A2 rejections developed and 13% of
our patients who had a single A3 episode. No patients
had more than 1 A3 episode.
Thirty-four patients (34/71, 48%) showed develop-
ment of either pathologically confirmed bronchiolitis
obliterans or clinically defined bronchiolitis obliterans
syndrome at a median follow-up of 40 months. Their
survival at 5 years was 36% (±9%) versus the 72%
(±10%) survival for those patients in whom bronchioli-
tis obliterans or bronchiolitis obliterans syndrome did
not develop (n = 37). This difference in survival was
highly significant by log-rank test (P = .008). Log-rank
analysis demonstrated no significant association
between early acute rejection and the incidence of
bronchiolitis obliterans for those patients who showed
rejection on the 1-month biopsy (Fig 4; n = 32, P =
.31), on the 3-month biopsy (n = 34, P = .18), or on the
6-month biopsy (n = 34, P = .65). Also, there was not a
significant association between grade of rejection
(patients with at least 1 episode of moderate or severe
rejection, n = 18) and bronchiolitis obliterans/bronchi-
olitis obliterans syndrome (P = .68).
In 5 of the 71 patients who survived 1 year,
cytomegalovirus disease developed (Tables I and II).
Twenty-one patients were treated with total lymphoid
irradiation for bronchiolitis obliterans syndrome or
bronchiolitis obliterans as noted in Tables I and II.
The morbidity related to transbronchial biopsies
included 5 cases of pneumothorax necessitating chest
tubes on 2 occasions. Bleeding that necessitated obser-
vation occurred in fewer than 5% of the 209 biopsies
and in one case the bleeding was severe.
Discussion
Bronchiolitis obliterans remains the major limitation
to the long-term success of lung transplantation.13,14
Experimental work would suggest it is an immune-
mediated phenomenon.15,16 Other investigators have
drawn a link between acute rejection and bronchiolitis
obliterans and therefore survival.3,14,17,18
In this study we did not find an association between
acute rejection and bronchiolitis obliterans. Another
published study from Washington University in St
Louis also did not observe a statistically significant
connection between early acute rejection and bronchi-
olitis obliterans.19 In that study 94 (84%) of 112
patients survived at least 3 months and formed the basis
for their analysis. They found that in 54 of the patients
bronchiolitis obliterans did not develop and in 40
patients bronchiolitis obliterans did develop but that
there was no statistically significant difference between
the number of acute rejection episodes occurring with-
in 90 days of the transplantation for those 2 groups (P
= .43).
The possible explanations as to why the group from
Washington University and our group did not find a link
The Journal of Thoracic and
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Table III. Transplant cohort (N = 96): perioperative
profile
Sex
Male 45
Female 51
Age (y)
Median 46.5
Range 16-68
Mortality*
Percent 7
No. 7/96
LOS (d)
Median 22.5
Range 7-162
Transplant
Single
Right 37
Left 32
Double 27
Indication
Emphysema 47
Cystic fibrosis 20
IPF 14
PPH 10
Other 5
Actuarial survival (%)
One month 93
One year 74
Two years 62
Three years 56
Five years 40
Follow-up (mo)
Median 40
Range 1-100
LOS, Length of stay; IPF, idiopathic pulmonary fibrosis; PPH, primary
pulmonary hypertension.
*Mortality is 30-day or in-hospital, whichever was longer.
may lie in part in the immunosuppressive regimen used
early after lung transplantation. Bando and colleagues3
observed high-grade rejection or multiple moderate
grade rejections in close to 50% of their patients.
Wallwork’s group from the United Kingdom did not
specify the grade of the biopsy results, but observed that
one third of their group showed more than 3 episodes of
acute rejection.14 In our study, we observed high-grade
rejection or multiple moderate grade rejection events in
less than 3% of our study population. The regimen used
by both of the above-mentioned groups was less aggres-
sive than the regimen detailed in the present study.
Bando’s group only used induction therapy with anti-
lymphocyte globulin for half the study and significantly
limited the use of steroids. Prior reports from Wallwork
and his colleagues described only a 3-day regimen of
antilymphocyte globulin and a very limited regimen of
steroids.4,5,7
The present study did not demonstrate decreased sur-
vival in those patients who were found to have acute
rejection on surveillance transbronchial biopsy. An
association between acute rejection and bronchiolitis
32 Swanson et al The Journal of Thoracic and
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Fig 1. Kaplan-Meier survival curves (95% CI) for 32 patients in whom the 1-month transbronchial biopsy result
showed rejection (solid lines) versus 39 patients in whom it did not (dashed lines).
Fig 2. Kaplan-Meier survival curves (95% CI) for 34 patients in whom the 3-month transbronchial biopsy result
showed rejection (solid lines) versus 35 patients in whom it did not (dashed lines).
obliterans/bronchiolitis obliterans syndrome was not
observed. The severity of the acute rejection episodes
and the number of persistent cases of acute rejection
were found to be quite low with this careful surveil-
lance and treatment strategy. The immunosuppressive
regimen detailed in this report is intensive both in terms
of the induction scheme and the dosage and duration of
steroid administration.
The survival seen in our overall group is similar to
that reported by the United Network for Organ Sharing
in its most recent publication.2 This fact coupled with
our results suggests several possible explanations.
Surveillance transbronchial biopsies, in the patient free
of symptoms, do not predict for bronchiolitis obliterans
and survival particularly when the acute rejection
episode is only mild (grades 1-2). Early transbronchial
biopsies in general do not correlate with the chronic
process of bronchiolitis obliterans, the cause of the
majority of late deaths. Aggressive early immunosup-
pression eliminates or uncouples the discriminating
The Journal of Thoracic and
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Fig 3. Kaplan-Meier survival curves (95% CI) for 34 patients in whom the 6-month transbronchial biopsy result
showed rejection (solid lines) versus 33 patients in whom it did not (dashed lines).
Fig 4. Kaplan-Meier survival curves (95% CI) for the outcome bronchiolitis obliterans (OB) for 32 patients in
whom the 1-month transbronchial biopsy result showed rejection (solid lines) versus 39 patients in whom it did
not (dashed lines).
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Table IV. ISHLT grade for 53 patients with acute rejection in first 6 months
ISHLT grade
At least 1 episode 
Survival days of moderate/severe 
Patient from TX Status Biopsy 1 Biopsy 2 Biopsy 3 rejection
4 715 D A1B1 Neg A1B1 No
5 592 D A1B0 A1B0 A1B1 No
6 3052 A Neg Neg A1B0 No
7 2935 A Neg A1B0 Neg No
8 807 D A0B1 Neg Neg No
9 1525 D Neg A1B1 Neg No
11 779 D Neg Neg A1B0 No
12 1440 D Neg A0B1 A1B1 No
14 1853 D Neg A1B0 Neg No
16 891 D Neg Neg A1B0 No
17 726 D Neg A0B3 A0B2 Yes
18 2275 A A0B2 A1B0 A3B2 Yes
21 516 D A0B1 Neg Neg No
23 1767 D Neg A0B2 Neg No
24 2005 A A1B3 A1B1 Neg Yes
25 921 D Neg Neg A1B0 No
26 1057 D A2B0 A2B3 A1B1 Yes
28 1769 A A0B3 A0B3 A1B0 Yes
29 1589 A Neg Neg A0B2 No
31 1531 A A2B0 Neg Neg No
33 1487 D A0B3 Neg Neg Yes
34 1530 A Neg A3B3 A2B2 Yes
35 1005 D Neg A3B2 A0B2 Yes
37 445 D Neg A0B2 Neg No
38 1515 A A1B0 Neg Neg No
39 1502 A Neg A2B0 A1B0 No
40 1474 A A3B3 Neg A2B2 Yes
41 1443 A A1B0 A1B0 A0B1 No
42 445 D A3B2 A2B0 A2B0 Yes
44 1398 A A1B0 Neg A1B0 No
47 416 D Neg A2B1 Neg No
48 1320 A A3B2 A1B1 A2B0 Yes
49 1193 D A1B0 Neg A1B0 No
50 1317 A Neg A2B0 A3B0 Yes
51 444 D A4B0 Neg Neg Yes
52 1223 A A2B0 A2B2 A0B2 No
54 1167 A Neg A0B3 Neg Yes
55 1164 D A2B0 Neg Neg No
56 1160 A A1B0 A3B0 A1B0 Yes
57 1135 A A0B4 A0B1 A3B1 Yes
59 1100 A Neg A2B2 A0B2 No
60 1065 A A2B0 Neg Neg No
61 1040 A Neg Neg A2B0 No
62 979 A A0B2 Neg Neg No
63 373 D Neg A0B1 A1B1 No
64 861 A Neg A2B0 A0B2 No
65 811 A A2B2 A2B0Cb A1B0 No
66 751 A A3B0 A1B0 Neg Yes
67 726 A Neg A1B0 Neg No
68 701 A A1B0 A1B0 Neg No
69 668 A A1B2 Neg A0B1Ca No
70 664 A A2B0 A0B3 Neg Yes
Data as of May 1999. TX, Transplantation; D, dead; Neg, negative; A, alive.
ability (variability in severity and persistence) of early
transbronchial biopsy to predict later outcome (bron-
chiolitis obliterans/bronchiolitis obliterans syndrome
or survival). Once the effects of the intensive early
immunosuppression have waned, as the time from the
antilymphocyte globulin treatment becomes greater
and the steroids are weaned, the link between the his-
tologic findings on transbronchial biopsy and the later
chronic fibrotic process may become more apparent.
Whether continued high-dose standard immunosup-
pression would prevent the emergence of later chronic
rejection, as suggested by some animal models,20 is not
a practical question for human beings given the com-
plications of prolonged high-dose immunosuppression,
such as infection, and the catabolic effects of high-dose
steroid treatment.
The findings of minimal, severe, early, or persistent
early rejection documented on surveillance trans-
bronchial biopsies in this study do raise the notion that
if a better immunosuppression regimen could be iden-
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Fig 5. Kaplan-Meier survival curves (95% CI) for the outcome bronchiolitis obliterans (OB) for 34 patients in
whom the 3-month transbronchial biopsy result showed rejection (solid lines) versus 35 patients in whom it did
not (dashed lines).
Fig 6. Kaplan-Meier survival curves (95% CI) for the outcome bronchiolitis obliterans (OB) for 34 patients in
whom the 6-month transbronchial biopsy result showed rejection (solid lines) versus 33 patients in whom it did
not (dashed lines).
tified then perhaps one could continue to suppress the
immunologic differences that are manifested as rejec-
tion. This regimen would need to be intense and cer-
tainly more specific. Indeed, specific tolerance would
be the ideal.
In the meantime, better discriminators of long-term
outcome must be identified. Exhaled nitric oxide levels
have been shown to correlate with acute rejection in
animal models and human beings after lung transplan-
tation.21 Interestingly, though, in the human data,
exhaled nitric oxide levels did not correlate with bron-
chiolitis obliterans.22 Again, there is some hint that the
acute and chronic rejection may be related but have dif-
ferent mechanisms. Alternatively E-selectin, an adhe-
sion molecule induced by activated lymphocytes and
cytokines, has been reported to be expressed in both
acute rejection and bronchiolitis obliterans.23
There are obvious limitations to the current method
of detecting acute rejection. Although surveillance
transbronchial biopsies are quite safe, they may not
have the discriminating ability that is necessary to have
an impact on the process of bronchiolitis obliterans
and, therefore, long-term survival. It may also be that
our current immunosuppressive combinations are rea-
sonably good at suppressing the phenomenon of early
acute rejection, but that they do not prevent bronchioli-
tis obliterans, which, although related, may have differ-
ent mechanisms or only require low-level immunolog-
ic activation.
In a manner analogous to the approach to lung cancer
of several decades ago, it would seem that we need to
continue carefully and completely to collect data that
pertain to an apparently insurmountable process if we
are going to make strides. It is mandatory that we con-
tinue to collect information that will provide insight
into the phenomenon of acute and chronic rejection. To
make lung transplantation a more broadly successful
and applicable technology, we must answer the prob-
lem of bronchiolitis obliterans. Aggressive and more
sensitive detection methods linked with better immuno-
suppression are needed.
We acknowledge and greatly thank Elizabeth N. Allred for
statistical revisions. We extend our deep appreciation to Judi
Hansjon and Mary Visciano for their editorial assistance and
expert advice.
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Discussion
Dr Thomas M. Egan (Chapel Hill, NC). Bronchiolitis
obliterans has become the scourge of patients with lung trans-
plants after they have been delivered from a wretched exis-
tence of suffocation, and it cuts short lives that transplanta-
tion intends to extend. It is the leading cause of death after the
first year following transplantation, and some studies suggest
that it is the inevitable outcome of transplantation, with actu-
arial freedom from bronchiolitis obliterans reported near 0%
10 years after lung transplantation.
Several factors have been implicated as etiologic agents or
as risk factors for the development of bronchiolitis obliterans,
including the number of acute rejection episodes and a vari-
ety of infections, including infection with cytomegalovirus. If
acute vascular rejection contributes to long-term graft dys-
function, then it is intuitive that attempts to detect this and
treat it might have a favorable impact on outcome, both from
the point of view of development of bronchiolitis obliterans
and ultimately of survival.
To assess the importance of biopsies in the treatment of
patients with lung transplants, the authors of this study at the
Brigham and Women’s Hospital retrospectively analyzed the
results of biopsies in 71 consecutive lung transplant recipi-
ents in whom 1-year follow-up was available. No matter
whether 1, 2, or 3 biopsy results were positive for acute rejec-
tion, this had no apparent impact on survival or, by χ2 analy-
sis, on the presence of bronchiolitis obliterans at the time of
this analysis.
The authors surmise that their more aggressive early
immunosuppression may have in some way uncoupled acute
rejection from the development of bronchiolitis obliterans,
but there may be other explanations. My first question for the
authors is, did you actually show convincingly that biopsy
outcome was not related to the development of bronchiolitis
obliterans syndrome? Only 11 patients had 3 positive biopsy
results, and while the χ2 test did not reach significance, do
you believe that a long enough time elapsed for this observa-
tion to hold?
You state in your manuscript that total lymphoid irradiation
was used in 21 patients with “persistent acute rejection.” This
is a large proportion of your patients and represents an unusu-
ally large experience with this treatment modality. Pre-
sumably for these patients to have persistent rejection, many
of them would have been in the positive biopsy cohort that
you studied. Was there an association between positive biop-
sy results and the subsequent treatment with total lymphoid
irradiation? If so, can you speculate as to whether total lym-
phoid irradiation might have interfered with the development
of bronchiolitis obliterans? If you stand by your observation
that biopsy outcome has no impact on survival, then should
we persist in doing biopsies?
One other unusual feature of your practice is the use of
ganciclovir for an entire year. You observed the development
of cytomegalovirus after cessation of treatment in 5 patients.
Are you not convinced yet that in a mismatch situation
cytomegalovirus disease is inevitable and the prolonged use
of prophylaxis may aid the emergence of ganciclovir-resis-
tant strains?
When we reported our results in patients with cystic fibro-
sis at the Southern Thoracic Surgical Association meeting a
year and a half ago, we too were unable to demonstrate a rela-
tionship between the number of acute rejection episodes and
outcome at 2 years or development of bronchiolitis. There are
broader questions that one can conjure up from your study
and others that should be answered in the future.
Is bronchiolitis obliterans really the pathologic hallmark of
chronic rejection as you stated in the introduction of your
manuscript or is it the inevitable sequela of lung transplanta-
tion? Phil Halloran, an immunologist at the University of
Alberta in Edmonton, put forward an interesting hypothesis
at the ISHLT last year. He suggested that chronic allograft
dysfunction in any transplanted organ could be a form of
accelerated senescence, which might be instigated by a vari-
ety of stressors to the organ.
Whatever the cause of bronchiolitis obliterans, our ability
to prevent it or reduce the incidence will have a substantial
impact on the lives of our transplant recipients.
Dr Swanson. You asked whether we think there was
enough time between the 3 persistent acute rejection biopsies
to determine whether bronchiolitis obliterans was going to
develop: the median follow-up period was 40 months, and I
think that time should be adequate.
As to the total lymphoid irradiation question, the major-
ity of patients who received this treatment were treated
once it was determined that they had bronchiolitis obliter-
ans, and the impetus for the treatment was not persistent
acute rejection. This should be clarified, because most of
these patients already had bronchiolitis obliterans when
they were treated with total lymphoid irradiation. Dr
Ingenito presented that data at the American Thoracic
Society, I believe 2 years ago, and the treatment did appear
to halt the progression and stabilize the condition in more
than half that group.
I think your question about whether we should continue to
do biopsies is right on. I think that we could not show a differ-
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ence, and one way to interpret this result would be that those
patients we treated were elevated to do as well as the others.
Even if that is not the case, I think we still need to do biopsies
because they have low morbidity and do provide us with evi-
dence and data from which we can make further strides. Unless
we continue to push, we are not going to make progress.
Most of the reports show a much higher incidence of
cytomegalovirus infection than the 6% we saw in our series.
I think it is not clear how long prophylactic ganciclovir
should be used, but I do think we have a low prevalence of
cytomegalovirus disease in our cohort.
Dr David W. Wormuth (Rochester, NY). By choosing 1-
year survival, did you preselect the patients who were already
going to survive an early rejection? Also, did your trans-
bronchial biopsy results predict mortality between 6 months
and 1 year?
Dr Swanson. We were mainly trying to look at survival
and bronchiolitis obliterans, and that is why we used a group
that had 1-year survival. Most of the data now show that sur-
vival to a year is pretty good. The problem is that from 1 year
to 5 years survival always drops off. To not complicate the
interpretation by using patients who died of other causes, we
wanted to limit the study to the 1-year survivors.
Dr David M. Follette (Sacramento, Calif). I would like to
amplify a bit, because, like Dr Egan, the way I interpret the
results is that perhaps we do not need to do surveillance biop-
sies in patients who do not have clinical indications. Should we
only do biopsies when there is clinical suspicion of rejection?
Do you believe that the routine biopsy in a patient who is oth-
erwise in clinically stable condition is of little or no benefit and
perhaps not necessary? I would like to have your thoughts on
whether you would interpret your study in the same way.
Dr Swanson. I think that is a good point. I think until we
actually suppress bronchiolitis obliterans, it may be that
we cannot show the difference that you would like to see, but
we did document a much less aggressive form of acute rejec-
tion. In the literature, most series show at least a third of the
patients have 3 or more episodes of acute rejection that is
moderate or severe in each cohort and more than half show
severe acute rejection. Thus what we found was a much less
significant or much less severe form of acute rejection, and
that may well be both from our augmented immunosuppres-
sion initially and the treatment of these mild episodes. Until
you can completely suppress the situation over the course of
several years, you may not see a difference, but I think ulti-
mately we may be able to do that. More important, however,
unless we continue to collect information and analyze it in
different ways, as I mentioned earlier, I do not think we will
make any progress. Thus I do think we still need to pursue
this kind of information.
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